We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 34.84%
2 Financials 13.62%
3 Communication Services 11.15%
4 Technology 9.41%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
$93.1M 0.46%
327,050
+100,168
+44% +$32.1M
PCG icon
52
PG&E
PCG
$38.5B
$85.4M 0.42%
7,292,042
– –
KRTX
53
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$81.2M 0.4%
675,000
-25,000
-4% -$2.83M
CLGX
54
DELISTED
Corelogic, Inc.
CLGX
$77.3M 0.38%
975,000
+400,972
+70% +$32M
BCAB icon
55
BioAtla
BCAB
$5.74M
$75.9M 0.38%
29,841
-9,500
-24% -$24.4M
BRMK
56
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$75M 0.37%
7,170,213
– –
RVMD icon
57
Revolution Medicines
RVMD
$44B
$73.9M 0.37%
+1,609,730
New +$72.2M
BPMC
58
DELISTED
Blueprint Medicines
BPMC
$67.6M 0.34%
+694,791
New +$69.4M
AGIO icon
59
Agios Pharmaceuticals
AGIO
$1.93B
$64.5M 0.32%
1,250,000
+250,000
+25% +$12.4M
KSU
60
DELISTED
Kansas City Southern
KSU
$63.3M 0.31%
240,000
-114,400
-32% -$24.9M
PTGX icon
61
Protagonist Therapeutics
PTGX
$9.44B
$62.8M 0.31%
2,425,000
– –
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
$59M 0.29%
850,000
+100,000
+13% +$7.69M
KYNB
63
Kyntra Bio
KYNB
$29.4M
$58.4M 0.29%
67,348
-8,652
-11% -$9.21M
CYTK icon
64
Cytokinetics
CYTK
$10.4B
$58.1M 0.29%
2,500,000
+100,000
+4% +$2.14M
PRAH
65
DELISTED
PRA Health Sciences, Inc.
PRAH
$53.7M 0.27%
+350,000
New +$47.5M
TVRD
66
Tvardi Therapeutics
TVRD
$23.4M
$53.5M 0.27%
68,472
– –
APHA
67
DELISTED
Aphria Inc. Common Shares
APHA
$50.8M 0.25%
+2,765,800
New +$44.8M
KRYS icon
68
Krystal Biotech
KRYS
$9.66B
$48.1M 0.24%
625,000
+100,000
+19% +$7.27M
LNTH icon
69
Lantheus
LNTH
$6.59B
$48.1M 0.24%
2,250,000
-400,000
-15% -$7.26M
BEAM icon
70
Beam Therapeutics
BEAM
$2.84B
$47.4M 0.24%
+592,481
New +$56.4M
TPTX
71
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$47.3M 0.24%
+500,000
New +$59.5M
ATTO
72
DELISTED
Atento S.A.
ATTO
$46.8M 0.23%
2,230,357
– –
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
$44M 0.22%
2,107,400
– –
ZGNX
74
DELISTED
Zogenix, Inc.
ZGNX
$43.9M 0.22%
2,250,000
– –
ANNX icon
75
Annexon
ANNX
$886M
$40.5M 0.2%
1,455,846
-101,415
-7% -$2.79M
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Farallon Capital Management held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Farallon Capital Management deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 38% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Farallon Capital Management's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Farallon Capital Management added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Farallon Capital Management's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Farallon Capital Management fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Farallon Capital Management's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Farallon Capital Management opened 120 new positions and closed 20 in Q1 2021.
  • Farallon Capital Management's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.